Haemostatic variables during normal menstrual cycle
Authors:
- Ramses F. J. KempermanRKRamses F. J. Kemperman
- Hanneke C. Kluin-NelemansHKHanneke C. Kluin-Nelemans
- André B. MulderAMAndré B. Mulder
- Karina MeijerKMKarina Meijer
- H. KnolHKH. Knol
- 1 January 2012
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 107 (01) , 22-29
Abstract
Summary: For a number of haemostatic factors menstrual cycle variation has been studied. Such variation could have clinical implications for the timing of haemostatic testing in women. It was our objective to systematically review the literature about evidence for timing of haemostatic testing during menstrual cycle.We searched MEDLINE, EMBASE and the Cochrane library to identify studies that measured haemostatic variables [platelet function, von Willebrand factor (VWF), factor VIII (FVIII), factor IX (FIX), factor XI (FXI), factor XIII (FXIII), D-dimer, plasminogen activator inhibitor-I (PAI-I), tissue plasminogen activator (tPA), urokinase-type plasminogen activator (uPA), α2-antiplasmin and fibrinogen] during normal menstrual cycle without hormonal contraceptives. Two investigators independently selected studies, and abstracted data in duplicate. We identified 1,046 studies of which we included 30 studies (25 longitudinal and 5 cross-sectional studies). All studies reported on haemostatic variables during menstrual cycle. Overall, most of the studies found no cyclic variation in VWF, FVIII, FXI, FXIII, fibrinolytic factors (PAI, t-PA, uPA, D-dimer and α2-antiplasmin) and fibrinogen. However, in studies where these variables showed any variation, they reached the lowest levels during menstrual and early follicular phase, especially for VWF, FVIII and platelet function tests. In conclusion, the optimal timing for haemostatic testing during menstrual cycle seems to be menstrual and early follicular phase.Keywords
This publication has 32 references indexed in Scilit:
- Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panelAmerican Journal of Obstetrics and Gynecology, 2009
- Menorrhagia associated with laboratory abnormalities of hemostasis: epidemiological, diagnostic and therapeutic aspectsJournal of Thrombosis and Haemostasis, 2007
- Effect of oral contraceptives and ovarian cycle on platelet functionPlatelets, 2007
- Bleeding Disorders in Premenopausal Women: (Another) Public Health Crisis for Hematology?Hematology-American Society Hematology Education Program, 2006
- Dynamic Variability of Hemostatic and Fibrinolytic Factors in Young WomenThe Journal of Clinical Endocrinology & Metabolism, 2004
- von Willebrand disease in women with menorrhagia: a systematic reviewBJOG: An International Journal of Obstetrics & Gynaecology, 2004
- Variations in Coagulation Factors in Women: Effects of Age, Ethnicity, Menstrual Cycle and Combined Oral ContraceptiveThrombosis and Haemostasis, 1999
- Frequency of inherited bleeding disorders in women with menorrhagiaThe Lancet, 1998
- Variation in risk indicators of cardiovascular disease during the menstrual cycle: An investigation of within-subject variations in glutathione peroxidase, haemostatic variables, lipids and lipoproteins in healthy young womenScandinavian Journal of Clinical and Laboratory Investigation, 1996
- Coagulation and Fibrinolysis during the Normal Menstrual CycleUpsala Journal of Medical Sciences, 1989